Abstract
Purpose
To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in central serous chorioretinopathy (CSCR).
Methods
In this prospective, placebo-controlled trial, sixty patients with persistent CSCR were assigned to three treatment group. Twenty patients in Group 1 were treated with 25 mg of spironolactone (Aldactone; Pfizer) for 1 week, then increased to 50 mg for the following 3 weeks, then shifted to eplerenone 50 mg for 1 month. Twenty patients in Group 2 were treated with 25 mg of eplerenone (Inspra; Pfizer) for 1 week, then increased to 50 mg for the following 3 weeks, and then shifted to spironolactone 50 mg for 1 month. Twenty patients in Group 3 were treated with 1 placebo control tablet for 1 week, then increased to two tablets for the following 3 weeks, and then shifted to spironolactone 50 mg for 1 month. At the end of the second month, all the treatments were stopped, and the patients were followed for two additional months. Primary outcome measure was a change in BCVA at 1, 2, and 4 months. Secondary outcome was a change of >20 % in the size of SRF recorded with OCT at 1, 2, and 4 months of treatment.
Results
In terms of BCVA, treatment in Group 1 was effective from the first month (spironolactone, p value 0.01), and in Group 2 effective from the second month (shift to spironolactone, p value 0.004). Since the p value after the first month was 0.2 in Group 2, even with a larger sample, it would be difficult to see an efficacy of an eplerenone treatment after 1 month. As for the SRF, both in Group 1 and Group 2, both treatments were found to be equally effective after 1 month of administration (p values 0.004). At 4 months, only in Group 3, there was no statistical improvement of BCVA and SRF (p values 0.09 and 0.5).
Conclusions
Spironolactone is statistically superior to eplerenone in improving BCVA of patients with CSCR, while both drugs can be considered equally effective in promoting the reabsorption of SRF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118
Quin G, Liew G, Ho I-V et al (2013) Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 41:187–200
Tittl MK, Spaide RF, Wong D et al (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128:63–68
Haimovici R, Koh S, Gagnon DR et al (2004) Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology 111:244–249
Bouzas EA, Karadimas P, Pournaras CJ (2002) Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 47(5):431–448
Farman N, Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol Ren Physiol 280:F181–F192
Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig 122(7):2672–2679
Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F (2010) The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 24(9):3405–3415
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33(10):2096–2102
Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, Brandely ML, Couraud B, Farman N, Gaudric A, Chast F, Behar-Cohen F (2015) Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35(12):2505–2515
Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29:1469–1473
Carrai P, Pichi F, Bonsignore F, Ciardella AP, Nucci P (2015) Wide-field spectral domain-optical coherence tomography in central serous chorioretinopathy. Int Ophthalmol 35(2):167–171
Farman N, Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol Ren Physiol 280(2):F181–F192
Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M (2007) The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 5:e012
Colussi G, Catena C, Sechi LA (2013) Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 31(1):3–15
Struthers A, Krum H, Williams GH (2008) A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31(4):153–158
Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414
Steinle NC, Gupta N, Yuan A, Singh RP (2012) Oral rifampin utilization for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 96:10–13
Meyerle CB, Freund KB, Bhatnagar P et al (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946
Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936
Forooghian F, Meleth AD, Cukras C et al (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771
Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466
Chan W-M, Lai TYY, Lai RYK et al (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765
Bae SH (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152(5):784–792
Schaal KB, Hoeh AE, Scheuerle A et al (2009) Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 19:613–617
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
No conflicting relationship exists for any author.
Rights and permissions
About this article
Cite this article
Pichi, F., Carrai, P., Ciardella, A. et al. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37, 1115–1125 (2017). https://doi.org/10.1007/s10792-016-0377-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-016-0377-2